Disclosures for "Ocrelizumab and Cladribine had similar EDSS stability and safety profile in patients with highly active multiple sclerosis")
-
Dr. Alshawaf has nothing to disclose.
-
Dr. Ahmed has nothing to disclose.
-
Dr. Al-Hashel has nothing to disclose.
-
Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Bayer, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen, Novartis, Merck, Roche, Sanofi.